Advanced NanoTherapies' Dual-Drug Nanotech Balloon Aims to Remake Vascular Care

SANTA CLARA, CA – June 02, 2026 – In a significant vote of confidence from the market, clinical-stage medtech firm Advanced NanoTherapies (ANT) has closed an oversubscribed Series B financing round exceeding $31 million. The funding, co-led by S3 Ventures and an undisclosed strategic investor, is set to accelerate the development of a technology that could fundamentally alter the treatment landscape for millions suffering from coronary and peripheral artery disease.

At the heart of this investment is SirPlux Duo, a first-of-its-kind drug-coated balloon (DCB) that leverages a proprietary nanoparticle delivery system. Unlike existing therapies, it delivers two synergistic drugs—paclitaxel and sirolimus—directly into the arterial wall. This fresh capital injection will fuel the company’s push for U.S. regulatory approval, advance crucial clinical trials, and expand its platform into challenging below-the-knee (BTK) applications, signaling that the early innings of a major shift in vascular intervention are now underway.

A New Paradigm in Drug Delivery

The standard of care for blocked arteries has long been a choice between drug-eluting stents (DES), which leave a permanent metal scaffold behind, and first-generation drug-coated balloons, which deliver a single crystalline drug with passive, and often inconsistent, absorption. Both approaches face the persistent challenge of restenosis—the re-narrowing of the artery due to cellular proliferation at the treatment site.

Advanced NanoTherapies aims to solve this problem by creating an entirely new category of therapy. The SirPlux Duo platform, exclusively licensed from the world-renowned Cleveland Clinic, uses biodegradable nanoparticles to actively shuttle two proven antiproliferative agents into the vascular cells. This dual-drug, nanoparticle-enabled approach is designed for controlled cellular uptake and sustained tissue retention, a combination intended to deliver higher potency at lower doses.

"This financing milestone arrives at a pivotal moment in vascular intervention," said Marwan Berrada-Sounni, CEO of ANT. "First-generation single drug DCBs are gaining traction in the U.S. market, but they continue to expose the limitations of passive crystalline drug delivery." He asserts that ANT is now "uniquely positioned to advance the field through a differentiated nanoparticle-enabled approach to local vascular therapy, which is long overdue."

This sentiment is echoed by leading clinicians. The combination of paclitaxel for a rapid effect and sirolimus for sustained inhibition, delivered precisely where needed, targets the biological mechanism of restenosis more effectively. "The creation of a new DCB category using two rather than one drug is a leapfrogging moment in vascular intervention," noted Azeem Latib, MD, Medical Director of Structural Heart Intervention at Montefiore Einstein. Dr. Latib highlighted the potential for outcomes non-inferior to stents while preserving the increasingly valued "leave nothing behind" strategy, which keeps future treatment options open for patients.

The Financial Blueprint for Disruption

The oversubscribed nature of the $31 million Series B round is a clear market indicator of the technology's disruptive potential. The involvement of S3 Ventures, a Texas-based firm known for its patient capital approach backed by a philanthropic foundation, suggests a long-term strategic vision. This model is well-suited for the lengthy and capital-intensive development cycle of breakthrough medical devices.

"This financing validates the strength of ANT's platform and the momentum built across science, clinical execution, and regulatory readiness," stated Brian R. Smith, Managing Director at S3 Ventures. The funding provides a critical runway for ANT to navigate the complex pathway to commercialization.

Immediate priorities for the capital include scaling up manufacturing to meet the stringent Investigational Device Exemption (IDE) requirements set by the U.S. Food and Drug Administration (FDA). This is a non-trivial undertaking, as producing a consistent, sterile, dual-drug nanoparticle coating at scale presents significant technical challenges. The funds will also directly support IDE submissions for two key coronary indications—in-stent restenosis and small-vessel de novo lesions—and an early feasibility study for below-the-knee applications.

Navigating the Clinical and Regulatory Gauntlet

Advanced NanoTherapies is not starting from scratch. The company has already built a solid foundation of clinical evidence. A first-in-human study involving 28 patients across Australia, the Dominican Republic, and New Zealand showed promising results, with a two-year follow-up revealing no new treatment failures. Furthermore, an ongoing 30-patient study in Spain is designed to mirror the protocol for a future U.S. pivotal trial, providing a bridge to domestic clinical execution.

A major tailwind for the company is the FDA Breakthrough Device Designation granted to SirPlux Duo. This status is reserved for technologies that may provide more effective treatment for life-threatening or irreversibly debilitating conditions. It provides ANT with an expedited path and more collaborative engagement with the FDA, potentially streamlining the review and approval process.

"Restenosis after PCI (percutaneous coronary intervention) continues to be a meaningful clinical challenge, largely driven by cell proliferation at the treatment site," explained Rishi Puri, MD, an interventional cardiologist at Cleveland Clinic. He emphasized the novelty of the platform, which "aims to deliver two drugs simultaneously to the lesion site using functionalized nanoparticles, enabling sustained local drug retention at lower doses."

Reshaping Patient Outcomes and Market Dynamics

The ultimate promise of SirPlux Duo lies in its potential to transform care for patient populations with limited options. In-stent restenosis remains a vexing problem, and treating small, delicate vessels with stents can be suboptimal. The most significant impact, however, may be in below-the-knee peripheral artery disease, a severe condition common in diabetic patients that carries a high risk of amputation. An effective, non-implant-based therapy could be a game-changer for limb salvage.

ANT's strategy is ambitious, aiming not just to compete with but to redefine the DCB market. Success will hinge on execution—navigating the complexities of manufacturing scale-up, generating robust data from pivotal trials, and convincing clinicians and payers of the technology's superior value. The competitive landscape is formidable, populated by medtech giants with deep pockets and established market channels. However, with strong investor backing, a clear regulatory advantage, and a technology that addresses a core clinical need, Advanced NanoTherapies is well-equipped for the challenge. With a robust financial runway and a clear regulatory path, the company is now focused on executing the complex manufacturing and clinical steps required to bring this next-generation therapy to patients.